secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001819790-22-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q2 net loss $5.7M; TP-03 NDA submission for Demodex blepharitis on track
-------------------------------------------------------------------------------

- Net loss of $5.7M vs net income of $6.3M in Q2 2021; revenue $15.3M from LianBio partnership.
- Cash and equivalents $245.4M as of June 30, 2022; runway into at least 2026.
- TP-03 met all endpoints in Saturn-2 Phase 3; NDA submission expected in H2 2022.
- Initiated Ersa Phase 2a trial of TP-03 for Meibomian Gland Disease.
- Expecting Phase 1b data for TP-05 Lyme disease prevention in H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000029/0001819790-22-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000029/tars-20220811.htm
  HTML page:      https://secwatch.observer/filing/0001819790-22-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer